Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study

• Published in: Thyroid (New York, N.Y.) Vol. 28; no. 2; p. 229
• Main Authors: Côrtes, Marina Carvalho Souza, Rosario, Pedro Weslley, Oliveira, Luís Fernando Faria, Calsolari, Maria Regina
• Format: Journal Article
• Language: English
• Published: United States 01.02.2018
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Autoantibodies - blood; Female; Humans; Male; Middle Aged; Neck - diagnostic imaging; Prognosis; Prospective Studies; Thyroglobulin - blood; Thyroglobulin - immunology; Thyroid Cancer, Papillary - blood; Thyroid Cancer, Papillary - diagnostic imaging; Thyroid Cancer, Papillary - immunology; Thyroid Cancer, Papillary - surgery; Thyroid Neoplasms - blood; Thyroid Neoplasms - diagnostic imaging; Thyroid Neoplasms - immunology; Thyroid Neoplasms - surgery; Thyroidectomy; Treatment Outcome; Ultrasonography; Young Adult; antithyroglobulin antibodies; thyroid cancer; interference; thyroglobulin
• ISSN: 1557-9077
• DOI: 10.1089/thy.2017.0350

Interference of antithyroglobulin antibodies (TgAb) with serum thyroglobulin (Tg) can occur even at detectable TgAb concentrations below the reference limit (borderline TgAb). Thus, borderline TgAb is considered as TgAb positivity in patients with thyroid cancer. This prospective study evaluated patients with papillary thyroid carcinoma with undetectable Tg and normal neck ultrasonography (US) after total thyroidectomy and ablation with I, and compared tumor persistence/recurrence and long-term Tg and TgAb behavior in those with borderline versus undetectable TgAb. A total of 576 patients were evaluated, divided into two groups: group A with undetectable TgAb (n = 420), and group B with borderline TgAb (n = 156). Groups A and B were similar in terms of patient and tumor characteristics. The time of follow-up ranged from 24 to 120 months. During follow-up, 11 (2.6%) patients in group A and 5 (3.2%) in group B developed a recurrence (p = 0.77). In group A, recurrences occurred in 9/390 patients who continued to have undetectable TgAb and in 1/9 patients who progressed to borderline TgAb. In group B, recurrences were detected in 1/84 patients who progressed to have undetectable TgAb, in 1/45 who still had borderline TgAb, and in 3/12 who developed elevated TgAb. In the presence of Tg levels <0.2 ng/mL, recurrences were detected in 2/486 patients with undetectable TgAb, in 0/67 with borderline TgAb, and in 3/12 with elevated TgAb. The results of post-therapy whole-body scanning (RxWBS) of 216 patients with Tg ≤0.2 ng/mL and normal US at the time of ablation were also analyzed. In low-risk patients, none of the 40 patients with borderline TgAb and none of the 94 with undetectable TgAb exhibited ectopic uptake on RxWBS. In intermediate-risk patients, lymph node metastases were detected by RxWBS in 1/25 (4%) with borderline TgAb and in 2/57 (3.5%) with undetectable TgAb. The results suggest that among low- or intermediate-risk patients with undetectable Tg and normal US after thyroidectomy, those with borderline TgAb are at no greater risk of tumor persistence or recurrence than those with undetectable TgAb. When undetectable Tg levels persist, recurrence should be suspected in the case of a TgAb elevation above the reference limit.